ARB 1598

Drug Profile

ARB 1598

Alternative Names: ARB-1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-GbG10; CYT003-QbG10; Immunodrug™ CYT003-QbG10; QbG10

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Checkmate Pharmaceuticals; Cytos Biotechnology; Genocea Biosciences
  • Class Allergy immunotherapies; Antiallergics; Oligonucleotides
  • Mechanism of Action Immunomodulators; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 14 Dec 2016 Genocea Biosciences and Checkmate Pharmaceuticals agree to co-develop ARB 1598 in USA for Malignant Melanoma
  • 04 Aug 2016 Discontinued - Preclinical for Hepatitis B in Canada (SC)
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top